Brexit: MHRA Grilling Gives A Regulator's View Of The Stakes
This article was originally published in SRA
Many of those in the life sciences sector who would be affected by a possible UK departure from the EU, including industry, scientists, the academic community and lawyers, have been happy to make their views known as to the likely effects. The voice of the drug regulators in this debate, though, has been understandably muted.
You may also be interested in...
UK vote to leave the EU opens the prospect of years of negotiations over the union's future relationship with one of its most valued member states.
UK referendum on whether to remain in EU will take place around the time that the Unified Patent Court is expected to launch.
A legislative provision under which future COVID-19 vaccines can be made available in the UK before they are approved is also being used to offer an unlicensed flu vaccine that officials say has undergone full safety, efficacy and quality tests.